Prophylactic low-molecular-weight heparin: prescription practice in an intensive care unit

The aim of this study was to review the use of low-molecular-weight heparin (LMWH) in a medical intensive care unit.

Double-blind prospective study conducted in a 14-bed intensive care unit, covering all patients admitted over a 2-month period. A comparison with 2 guidelines based on indication, age of the patient, kidney function, platelet count, and duration of treatment was performed. Bleeding complication and clinically diagnosed phlebitis episodes were collected.

One hundred thirty-six patients (71 treated with LMWH and 65 untreated) were included in the study (mean age, 60 +/- 18 years; SAPS (Simplified Acute Physiology Score) II, 39 +/- 23). Among treated patients, 9 were overtreated (13%), and among nontreated patients, 13 were undertreated (20%). In the cohort of treated patients, reasons for failure to comply with recommendations included age of the patient (30%), creatinine clearance (18%), platelet count (32.4%), and duration of treatment (12.7%). Low-molecular-weight heparin prescriptions were conforming to the 4 criteria in 35.2% of patients, to 3 in 43.7%, to 2 in 19.7%, and to 1 in 1.4%.

The prescription of prophylactic LMWH in intensive care has become a routine. Our study shows that over- and underprescription are common together with misuse.